Analyst Explains Why Eli Lilly (LLY) GLP-1 Advantage is Decreasing

We recently published 10 Stocks to Watch Ahead of Q3 Earnings Season. Eli Lilly and Company (NYSE:LLY) is one of the stocks that Wall Street analysts are discussing these days. Don Kaufman of TheoTrade said in a recent program on Schwab Network that Eli Lilly And Co (NYSE:LLY) edge in the GLP-1 drugs is thinning as “every” pharma company has the capacity to make drugs like GLP-1 treatments. “You know, one of the things I think people have to recognize about GLP1 and some of the drugs in the pipeline righ ...